Upregulated miRNA‑182‑5p expression in tumor tissue and peripheral blood samples from patients with non‑small cell lung cancer is associated with downregulated Caspase 2 expression

Abstract

Lung cancer has the highest morbidity and mortality rates among all malignant tumors worldwide. Previous studies demonstrated that microRNA (miR)-182-5p may serve different roles in different types of cancer, including renal cell carcinoma and liver cancer. However, the functional role of miR-182-5p in non-small cell lung cancer (NSCLC) remains unknown. In the current study, the expression level of miR-182-5p in tumor tissue and peripheral blood samples obtained from patients with NSCLC was examined. The biological function of miR-182-5p on NSCLC cell proliferation was also investigated. Tissue and adjacent normal tissue samples were collected from 33 patients with NSCLC. In addition, peripheral blood samples were obtained from patients with NSCLC and 26 healthy control patients. The NSCLC cell line H1299 was used for all functional assays. Reverse transcription-quantitative polymerase chain reaction was used to determine the miR-182-5p or Caspase 2 (CASP2) mRNA expression levels in NSCLC tissue and peripheral blood samples, as well as in the NSCLC cell line. Western blotting was used to examine the protein expression level of CASP2 in tissue samples and cells, and ELISA was performed to measure the protein level of CASP2 in peripheral blood samples. MTT assay was performed to examine NSCLC cell proliferation. Flow cytometry was used to detect apoptosis. Dual-luciferase reporter assay was used to examine whether miRN182-5p directly interacts with CASP2. The current study demonstrated that miR-182-5p expression was upregulated in NSCLC tissue and peripheral blood samples from patients with NSCLC, which suggests that miR-182-5p, may serve a functional role in NSCLC. In addition, inhibition of miR-182-5p expression suppressed cell proliferation and enhanced cell apoptosis in NSCLC cells. CASP2 expression was downregulated in NSCLC tissue and peripheral blood samples from patients with NSCLC. The current study demonstrated that miR-182-5p may regulate NSCLC cell proliferation and apoptosis by regulating CASP2 expression as miR-182-5p directly binds with the 3′-untranslated region of CASP2, thereby regulating CASP2 expression.

Ultrasound‑targeted microbubble destruction‑mediated miR‑767 inhibition suppresses tumor progression of non‑small cell lung cancer

“…An increasing number of studies have reported the important role of miRNAs in the treatment of various human cancers (23)(24)(25). The present study aimed to investigate the expressional patterns of miR-767 in NSCLC clinical samples and cells and to analyze the functional role of miR-767 in tumor progression.…”

Circulating miR-1246 Targeting UBE2C, TNNI3, TRAIP, UCHL1 Genes and Key Pathways as a Potential Biomarker for Lung Adenocarcinoma: Integrated Biological Network Analysis

“…The expression level of miRNA-33a plays a vital role in the progression of LUAD; it could be an ideal biomarker for the diagnosis and prognosis of LUAD patients who have received adjuvant chemotherapy [ 10 ]. Upregulated oncogenic miRNAs (miR-130b, miR-182-5p, miRNA-17, and miRNA-222) were reported to cause the development and progression of LUAD [ 11 , 12 , 13 ]; moreover, downregulated miRNAs (miR-486-5p, miR-101, miR-133a), also called tumor-suppressive miRNAs, were reported to repress the development of NSCLC [ 14 , 15 , 16 ]. miR-21 and miR-24 were significantly lower in ASO serum samples of lung carcinoma patients when compared to the samples of BSO patients.…”

Value of virtual bronchoscopic navigation and transbronchial ultrasound-guided sheath-guided exploration in diagnosis of peripheral lung cancer

“…Early peripheral lung cancer has no significant symptoms, and when the symptoms are obvious, the cancer is in a late stage. Globally, lung cancer has a high incidence and mortality rate[ 5 , 6 ]. If patients with peripheral lung cancer have advanced metastasis, it is necessary to have a clear molecular diagnosis based on different targets to initiate individualized treatment and promote a therapeutic effect.…”